# ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting

> **NCT04241315** · PHASE3 · COMPLETED · sponsor: **On Target Laboratories, LLC** · enrollment: 112 (actual)

## Conditions studied

- Lung Neoplasms
- Lung Cancer

## Interventions

- **DRUG:** OTL38 for Injection
- **DEVICE:** Near infrared camera imaging system

## Key facts

- **NCT ID:** NCT04241315
- **Lead sponsor:** On Target Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-26
- **Primary completion:** 2021-10-07
- **Final completion:** 2021-11-01
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04241315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04241315, "ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04241315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*